NEW YORK, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Tuesday, September 10 at 10:50 a.m. ET. The Conference will take place at the Millennium Broadway Hotel in New York, NY. A live webcast and 30-day archive of the event can be viewed on the Company's website at www.stemline.com.
About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline's clinical candidates, SL-401 and SL-701, have demonstrated clinical activity, including durable complete responses (CRs), in Phase 1/2 studies of patients with advanced hematological and brain cancer, respectively. For more information about Stemline Therapeutics, visit www.stemline.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.